Clinical Trial
Suicidality
This study formed part of a larger open-label clinical trial, Oral Ketamine Trial on Suicidality (OKTOS), conducted at the Thompson Institute between August 2018 and November 2019 (Oral Ketamine Trial on Suicidality (OKTOS) design.The trial included a broad range of clinical, neurophysiological, neuroimaging, and biochemical measures (i.e., MRI, EEG, blood tests, urinalysis, clinical scales). This study utilized data only from EEG recordings and 2 clinical scales. The primary clinical outcome measure was reduction in suicidality with ketamine treatment, and this was determined by Beck Scale for Suicide Ideation (BSS) (Ethics approval was obtained through the Bellberry Limited Ethics Committee (2017-12-982) and ratified by the University of the Sunshine Coast Human Research Ethics Committee (A181101). All study activities were conducted in accordance with the Australian National Statement on Ethical Conduct in Human Research (2007) and conformed with the Declaration of Helsinki ethical principles for medical research involving human subjects. This study was registered on the Australian Clinical Trials Registry ( The anonymized data that support the findings of this study are available from the corresponding author upon reasonable request.